Merck
CN
HomeProductsPharma & Biopharma ManufacturingBioprocessing Cell CultureViral Vector Upstream Platforms

Viral Vector Upstream Platforms

The image depicts a person in a laboratory setting, engaged in scientific work. They are wearing a white lab coat, blue gloves, and a hairnet, which indicates adherence to safety protocols. The individual is handling test tubes containing colored liquids, and various lab equipment and chemicals are arranged on the counter beside them. The background shows shelves stocked with additional lab supplies and equipment, emphasizing the professional and well-equipped nature of the laboratory.

Gene therapies in the market today use viral vectors to introduce modified genetic material into targeted cells. This means gene therapy manufacturing starts with the upstream production of vectors either through transient transfection or use of stable producer cell line which culminates in the harvesting of the viral vector produced. This feeds into downstream purification and concentration to ensure the product has high efficacy and safety to pass regulatory requirements. Therefore, making the right upstream process decisions not only impacts immediate upstream outputs, but also downstream processes, timelines and regulatory acceptance.

Four major challenges that face upstream manufacturing today include: High productivity, process robustness, scalability for commercial production, and product quality. Using optimized, time-effective upstream production platforms can help gene therapy manufacturers address key upstream challenges. Draw on our experience to learn how you can speed your gene therapy to patients.

Read more about

Request Information
Products
Loading

Related Product Resources

Lentivirus Manufacturing:

Are you looking for a platform that achieves best-in-class performance for lentivirus production?

  • The VirusExpress® 293T Lentiviral Production Platform offers a transfection-based solution to lentiviral (LV) production challenges, featuring a suspension adapted cell line, chemically defined medium, and process with proven performance at 50 L scale.

Adeno-associated Virus (AAV) Manufacturing:

Are you an AAV manufacturer looking for a high quality, high performance upstream platform?

  • The VirusExpress® 293 AAV Production Platform offers a transfection-based solution using a suspension adapted cell line, chemically defined medium, and a clinically relevant process dramatically reducing time to production.
  • Sf9 Rhabdovirus-Negative (Sf-RVN®) Platform provides a rhabdovirus-free cell line that improves the safety profile of your bioprocesses combined with a chemically defined medium specifically formulated to get excellent growth and productivity while adhering to regulatory requirements.
The image is a simplified illustration that depicts the process of converting a virus into a vaccine. It features a pink virus with yellow spikes at the top left, which is transformed into a blue vaccine vial at the bottom right after passing through two intermediary stages represented by bottles containing colorful substances. The transformation is indicated by arrows leading from the virus to the bottles and finally to the vaccine vial, emphasizing the stages of vaccine development. The background is white, highlighting the colorful elements of the illustration.

THE VIRUSEXPRESS® 293T LENTIVIRAL PRODUCTION PLATFORM

The VirusExpress® 293T Lentiviral Production Platform offers a transfection-based solution to LV production challenges, featuring a suspension adapted cell line, chemically defined medium, and process with proven performance at 50 L scale. The platform can dramatically reduce time in process development and scale-up, either within your own facilities or using our contract manufacturing capabilities to speed your therapy to patients. 

Key Advantages of VirusExpress® 293T Lentiviral Production Platform Include:

VirusExpress® 293T Lentiviral Production Cells

  • Cell line grows to high cell density and viability in suspension and has lower doubling time
  • Selected for higher lentivirus production using PEI-based transient transfection method
  • GMP-banked and fully characterized HEK 293T cells
  • Fully traceable and documentation available for regulatory filings
  • Licenses available for research or clinical/commercial use

EX-CELL® CD HEK293 Viral Vector Medium

  • Chemically defined, animal component-free cell culture medium
  • Supports high cell density and faster growth of HEK293T cells
  • Compatible with the PEI based transfection reagents used for viral production
  • No need for addition of boost and enhancer reagents for transfection step
  • Available in liquid and dry powder formats

Proven Process

  • Upstream production process optimized and demonstrated for performance from shake flasks to 50L bioreactor
  • Downstream process developed for purification of lentivirus at clinically relevant scale
  • Up to 40% reduction in process development and scale-up time

VirusExpress® 293T Lentiviral Production Platform Performance

Request Information
The image portrays a process where raw materials are converted into two bottles of chemicals, which are then used to complete a checklist on a clipboard. The top left features a large yellow circle with purple geometric shapes, symbolizing raw materials. These materials flow into two bottles—one taller and blue, the other shorter and green—representing their transformation into chemicals. Finally, an arrow leads from the bottles to a clipboard with green check marks, suggesting the successful use of these chemicals in fulfilling specific tasks or requirements. The illustration is simple and uses a color-coded scheme to convey the process flow clearly.

THE VIRUSEXPRESS® 293 AAV PRODUCTION PLATFORM

The VirusExpress® 293 AAV Production Platform offers a transfection-based solution using a HEK293 suspension adapted cell line, chemically defined medium, and a clinically relevant process dramatically reducing time to commercial production. The VirusExpress® Production Platform offers a higher vector yield than adherent platforms and a simpler process than competitor products. The VirusExpress® Production Platform has been optimized for AAV2, AAV5, AAV6 and other serotype production.

Key Advantages of VirusExpress® 293 AAV Production Platform Include:

VirusExpress® 293 AAV Production Cells

  • Cell line grows to high cell density and viability in suspension and has lower doubling time
  • Selected for higher rAAV production using PEI-based transient transfection method
  • GMP-banked and fully characterized HEK 293 cells
  • Fully traceable and documentation available for regulatory filings
  • Licenses available for research or clinical/commercial use

EX-CELL® CD HEK293 Viral Vector Medium

  • Chemically defined, animal component-free cell culture medium
  • Supports high cell density and faster growth of HEK293 cells
  • Compatible with the PEI based transfection reagents used for AAV production
  • No need for addition of boost and enhancer reagents for transfection step
  • Available in liquid and dry powder formats

Proven Process

  • Upstream production process optimized and demonstrated for performance from shake flasks to 50L bioreactor
  • Downstream process developed for purification of AAV at clinically relevant scale
  • Up to 40% reduction in process development and scale-up time

VirusExpress® 293 AAV Production Platform Performance

Request Information
The image depicts a process diagram for the Sf-RVN® Platform, illustrating the transformation of raw materials into a final product, symbolized by a butterfly logo labeled “upcycling,” which then leads to a clipboard with a checklist. This represents the platform’s streamlined workflow for converting the Sf-RVN® Insect Cell Line and EX-CELL® CD Insect Cell Medium into a high-quality, regulatory-compliant bioproduct, emphasizing the platform’s key advantages of improved safety, high performance, and flexible options.

THE Sf-RVN® PLATFORM

For Improving the Safety Profile of Your Baculovirus-Insect Cell Based Vaccines and Gene Therapies

The Sf-RVN® Insect Cell Line offers a rhabdovirus-free alternative and enhances risk mitigation. Together with the chemically defined medium, EX-CELL® CD Insect Cell Medium, forms the Sf-RVN® Platform, providing a high-performance platform optimal to produce adeno-associated vectors (AAV) for gene therapy applications.

Key Advantages of the Sf-RVN® Platform Include:

Sf-RVN® Insect Cell Line

  • Sf9 rhabdovirus-negative cell line
  • Adventitious agent tested and GMP banked in EX-CELL® CD Insect Cell Medium
  • Full traceability and documentation available for regulatory filings

EX-CELL® CD Insect Cell Medium

  • Chemically defined and animal component free
  • High reproducibility and lot-to-lot reliability
  • Supports growth of multiple insect cell lines
  • Optimized for the Sf-RVN® Insect Cell Line
  • Available in liquid and dry powdered medium

Benefits

  • Improved Safety - Enhanced risk mitigation with the rhabdovirus negative cell line
  • High Performance - Optimized to get high low doubling time, high cell viability and high AAV titer
  • Flexible Options - Several license agreement options available
  • Technical Support - Technical user guide with detailed protocols for optimal performances

The Sf-RVN® Platform Performance for Growth and AAV Production

Request Information

Related Videos

Slide 1 of 3

Related Webinars

The image is a vibrant digital illustration promoting a webinar titled “Driving the Viral Vector Expressway: Speeding Through AAV Manufacturing” by Henry George and Andi Ushijima, dated 06 October 2022. It features a blue train on a pink track, symbolizing speed and efficiency in AAV manufacturing, and includes the logo for SAFC Pharma & Biopharma Raw Material Solutions. The background is yellow and pink with abstract shapes to add visual interest.
Driving the Viral Vector Expressway: Speeding Through AAV Manufacturing

The production of AAV viral vectors for gene therapy comes with unique upstream challenges. Learn how our HEK platform can solve these challenges.

Related Product Categories
Bioprocessing Cell Culture Media
Our off-the-shelf and customizable bioprocessing cell culture media (CCM) products enhance productivity in upstream mAb, vaccine, gene/cell therapy processes.
Bioprocessing Cell Lines
Our ready-to-use, off-the-shelf cell line systems greatly reduce the time, cost, and risk of developing new cell lines for production. Whether you are producing antibodies, recombinant proteins, or viral vectors for gene therapies, our cell line platforms can accelerate your upstream progress.
Bioprocessing Mobius® Single-Use Bioreactors
The Mobius® Bioreactor family includes the bench scale (2 mL and 3 L), pilot, clinical and commercial manufacturing (50 – 2,000 L) single-use bioreactors that enable cell culturing capabilities from early process development through commercial batch production.
Upstream Process Chemicals
Optimize biopharma processes: top-tier upstream chemicals for research to commercialization. Reliability, transparency, regulatory support assured.
Media Filtration
Safeguard bioreactors with effective cell culture media filtration. Choose the right filter for contamination prevention.
Related Applications
Viral Vector Upstream Processing
Growing viral vectors for new gene therapies poses complex upstream decisions about raw material sourcing, cell culture media preparation, filtration, transfer, storage, and point of use. Choices made upstream can have a large impact on the downstream process.
Viral Vector Characterization and Biosafety Testing
As gene therapy products continue to show promise, biosafety testing and characterization remain a critical part of the development process. These vital steps help mitigate safety concerns and provide a better understanding of products and processes well in advance of patient administration.
Viral Vector Contract Development and Manufacturing
Producing new viral vector drugs demands specialized expertise that can be prohibitively expensive and time-consuming to develop. Partnership with an experienced contract manufacturer can integrate compliance, safety, and process development on a global scale, eliminating time and risk mitigation concerns.
Viral Vector Vaccine Manufacturing
A relatively templated manufacturing process can be used to produce live vector vaccines. Challenges exist, however, and include yield loss due to sterile filtration, vector aggregation and scaling adherent cultures. Learn all about this core platform technology and how expertise—empowered by collaboration— can overcome manufacturing challenges.
Related Services
Emprove® Program
Emprove® Program: The smart way to master compliance and control. Complementing our product portfolio, the Emprove® Program provides convenient access to reliable technical, regulatory and supply information in Emprove® Dossiers to support your risk assessment continuum.
Gene Therapy Process Development
With over 25 years of experience, we have the expertise to support robust process development of viral vectors for cell and gene therapies. Our process development strategies ensure that product quality and patient safety remain a top priority as your therapy progresses from discovery to commercialization.
Viral Vector Contract Testing, Development, & Manufacturing Services (CTDMO)
Millipore® CTDMO Services delivers expertise and flexible solutions for viral vector development and manufacturing to advance cell and gene therapies from preclinical through commercial production. Our proficiency with adeno-associated virus (AAV), lentivirus, adenovirus, and other vectors helps streamline the development and manufacturing.

Request Information

If interested in any of our upstream platforms above, please complete and submit the webform below for more information and begin bringing your gene therapy to life.

Fields indicated by a * are mandatory.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?